Smead Capital Hires BlackRock Veteran as New CFO

Hire adds depth to domestic and offshore operations

SEATTLE--(BUSINESS WIRE)-- Smead Capital Management, a Seattle-based registered investment advisor, announced today the hiring of Jameson Greenfield to the position of Chief Financial Officer. In his new role, Mr. Greenfield will oversee all financial aspects of the firm.

“We are excited to welcome Mr. Greenfield to the Smead team,” said Bill Smead, CEO and CIO of Smead Capital. “Mr. Greenfield’s extensive background and experience in fund administration and accounting puts our firm in a position to take advantage of the circumstances we see ahead. We look forward to our future as stock pickers with Jameson on board.”

Mr. Greenfield comes to Smead after serving in several leading roles at BlackRock. Most recently, he oversaw the operational support of BlackRock’s Hedge Fund and Private Credit platforms. In addition, Jameson served as a Board member for several Luxembourg-based investment funds and was an active member of BlackRock’s Alternatives Leadership Committee and Alternatives Operating Committee.

About Smead Capital Management

Smead Capital Management manages large cap portfolios for advisors, family offices and institutions with a value-oriented investment discipline. As of December 31, 2017, the firm managed approximately $2.3 billion in all accounts, including mutual funds. The firm was formed in July 2007 by CIO Bill Smead, who first created the firm’s investment discipline in 1993. For more information, visit http://www.smeadcap.com or call 1-877-701-2883.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180302005102/en/

Lyceus Group
Tucker Slosburg, 206-652-3205
[email protected]

Source: Smead Capital Management

You May Also Be Interested In

• The U.S. Is Pushing Chinese Drones Out. These 4 Stocks Could Fill the Gap (ZENA, RCAT, ONDS, UMAC)
• ID Dataweb to Join Expert Panel to Speak on AI-Augmented Identity Fraud at Florida Public Sector Cybersecurity Summit
• CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)